About EpimAb BiotherapeuticsEpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule.
CEO: Chengbin Wu, Ph.D
CBO: Dr. Stephan Lensky
Please click here for EpimAb's technology.
9 articles with EpimAb Biotherapeutics
Funding to be used in growing and advancing the Company’s clinical pipeline of novel bispecific antibodies
6/5/2019EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for process development and pilot manufacturing.
Patent protects EpimAb’s core technology FIT-Ig® and its entire bispecific pipeline with a broad composition of matter claim
First Patients Dosed with Company’s Novel Bispecific Antibody Format in Phase I/II Clinical Trial
IND Filing Marks Further Progress Towards the First Clinical Trial with the Company’s Novel Bispecific Antibody Format
EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer.
EpimAb Biotherapeutics Collaborates With Wuxi Biologics To Advance Lead Bispecific Antibody Candidate Towards Clinical Development
EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies
Kymab And EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement